Following this activity, participants should be able to: (1) Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on HR- and HER2- receptor status. (2) Assess the safety profile of agents used in management of metastatic HR-positive and HER2-negative metastatic breast cancer and outline strategies to optimally manage common toxicities. (3) Outline new and emerging therapeutic options for patients with metastatic breast cancer.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95052
- Start Date: 2024-03-06 06:00:00
- End Date: 2024-03-06 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False Source: Exelixis - Amount: 0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0 - Is Kind Support: False Source: Lantheus - Amount: 0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest